Watch PYXS. Know when insiders buy.
One email the day a filing lands. Free.
PYXS
Pyxis Oncology, Inc.
1.58
+0.00 +0.00%
USD · close Nov 13
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
79
PASS · shorts 79
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $131.8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$88.7MNET CASH —52W 1.06 – 5.34SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$26M | −$25.3M | — | -0.40 | −$18.2M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$24.4M | −$23.3M | — | -0.37 | −$26M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | $11M | — | — | −$18.3M | −$18.1M | — | -0.29 | −$10.4M | $0 | −$10.4M | Mar 23 |
| Q3 2025 · Sep 30 | $0 | — | — | −$23.5M | −$22M | — | -0.35 | −$13.3M | — | — | Nov 3 |
| Q2 2025 · Jun 30 | $2.8M | — | — | −$19.8M | −$18.4M | — | -0.30 | −$17.3M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$22.9M | −$21.2M | — | -0.35 | −$22.5M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$40.1M | −$35.6M | — | -0.59 | −$19.3M | $0 | −$19.3M | Mar 23 |
| Q3 2024 · Sep 30 | $0 | — | — | −$23.8M | −$21.2M | — | -0.35 | −$14.7M | $0 | −$14.7M | Nov 3 |
| Q2 2024 · Jun 30 | $0 | — | — | −$20M | −$17.3M | — | -0.29 | −$3M | $0 | −$3M | Aug 14 |
| Q1 2024 · Mar 31 | $16.1M | — | 97.1% | −$5.6M | −$3.3M | — | -0.06 | −$20.7M | $237K | −$20.9M | Aug 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$17.8M | −$15.6M | — | -0.33 | −$15.3M | $0 | −$15.3M | Mar 18 |
| Q3 2023 · Sep 30 | — | — | — | −$25.4M | −$23M | — | -0.56 | −$17.6M | $61K | −$17.6M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $13.9M | 82.8% | −$84.4M | −$79.6M | -574.5% | -1.28 | −$63.5M | $9K | −$63.5M | — | — |
| FY2024 · to Dec 31 | $16.1M | 97.1% | −$89.5M | −$77.3M | -478.9% | -1.32 | −$57.7M | $237K | −$57.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$82.2M | −$73.8M | — | -1.85 | −$70.7M | $6.7M | −$77.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$123.5M | −$120.7M | — | -3.65 | −$89.3M | $6.4M | −$95.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$69.7M | −$76M | — | -8.95 | −$35.3M | $540K | −$35.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$12.9M | −$12.8M | — | -12.45 | −$10.1M | $1.5M | −$11.6M | — | — |
Every number comes from Pyxis Oncology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.